First Anti-TL1A Drug Hits Its Mark in Ulcerative Colitis

Merck announced positive results from a large phase 3 trial testing tulisokibart, an experimental antibody for people with moderately to severely active ulcerative colitis who have not found lasting relief from existing treatments. Ulcerative colitis is a chronic autoimmune condition that inflames the lining of the colon, causing pain, bleeding, and frequent, urgent trips to the bathroom. Many patients cycle through several biologic drugs before finding one that works, and some never reach a symptom-free state called clinical remission.

Tulisokibart works differently than most currently approved ulcerative colitis drugs. Instead of blocking TNF or IL-23, the targets of older biologics, it targets a signaling protein called TL1A (short for tumor necrosis factor-like cytokine 1A), which plays a role in both inflammation and the scarring, or fibrosis, that can develop in the gut over time. Because of this dual role, TL1A has drawn a lot of interest across the pharmaceutical industry as a potential new class of inflammatory bowel disease treatment, and tulisokibart is now the first anti-TL1A drug to succeed in a pivotal trial.

The trial, called ATLAS-UC, was an induction-only study, meaning it measured how patients responded during roughly the first 12 weeks of treatment rather than over a full year. It met its primary goal: a significantly higher share of patients on tulisokibart reached clinical remission by week 12, based on a standardized scoring tool called the Modified Mayo Score, than those on placebo. The drug also met several secondary goals that matter clinically, including improvement seen during colonoscopy and healing of the tissue lining the colon, both signs that the inflammation is genuinely resolving rather than just symptoms being masked.

Merck reported that the safety profile was consistent with earlier, smaller studies of the drug, and no new safety concerns turned up in this larger patient group. That consistency matters because inflammatory bowel disease treatments are typically taken for years, so a clean safety record across multiple studies builds confidence heading into longer trials.

For patients, the significance goes beyond one company's drug. A successful anti-TL1A trial validates an entirely new treatment pathway, which means other companies developing similar drugs, and there are several in the pipeline, now have real-world proof that this approach can work. If tulisokibart continues to perform well in maintenance studies that test whether the benefit holds up over a longer period, and eventually reaches approval, it would give doctors another option for patients who have already tried and failed anti-TNF or anti-IL-23 biologics, a group that currently has limited choices left. Merck has not yet announced a timeline for regulatory filing, and these results have not yet undergone independent peer review.